Navigation Links
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
Date:9/4/2007

ming of completion of such trials; filings for regulatory approval in the United States and in the European Union and the timing of such filings as well as the scope of the indications that the Company is seeking approval for with respect to such filings; the potential markets for NGX-4010; the potential efficacy and benefits of NGX-4010; and NeurogesX' plans to commercialize NGX-4010, including with respect to sales force plans and plans to enter into commercial partnerships. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, subsequent analysis of data from NeurogesX' C117 trial may cause the results to be viewed less favorably as compared to NeurogesX' initial analysis of such trial's results; past results of clinical trials may not be indicative of future clinical trials results; NGX-4010 may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies and changing standards of care; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; NeurogesX' ability to obtain additional financing; NeurogesX' ability to obtain and maintain future commercial partnerships; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.

Stephen Ghiglieri

(650) 508-2116

The Ruth Group

Investors / Med
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... -- CytRx Corporation (NASDAQ: CYTR ), a ... that data regarding the Company,s Phase 2b global clinical ... tissue sarcoma (STS) will be presented in a moderated ... (CTOS) Annual Meeting which is being held October 15-18, ... the longer than expected survival of patients in the ...
(Date:10/16/2014)...  One of California,s most ... the Patient Advocate — this week recognized Kaiser Permanente,s ... state for the seventh consecutive year. The ... and Kaiser Permanente Southern California are the only health ... a four-star rating — the highest possible — for ...
(Date:10/16/2014)... YORK , Oct. 16, 2014 Curtis ... organizer is under 3 weeks away from hosting their co-located ... and Oral Drug Formulation Innovations Summit taking ... San Diego, CA. November,s ... development organizations in streamlining the bioequivalence testing process, as ...
Breaking Medicine Technology:CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 3CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 4CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 5CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 6Kaiser Permanente's California Health Plans Rated Highest for Quality for Seventh Consecutive Year 2Kaiser Permanente's California Health Plans Rated Highest for Quality for Seventh Consecutive Year 3Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2
... July 14 ERT (Nasdaq: ERES ) announced today that ... August 9, 2010 , after the market closes. After the release, the Company ... , , , ... participants should dial 1-800-860-2442 when calling within the United States or ...
... , HONOLULU , July 14 EnVivo ... on Alzheimer,s Disease (ICAD) results from its proprietary gamma-secretase modulator ... reduced amyloid plaque buildup which is believed to be a ... inflammation associated with Alzheimer,s disease. , ...
Cached Medicine Technology:ERT to Announce Second Quarter 2010 Results on August 9, 2010 2EnVivo Pharmaceuticals Announces Significant Results from GSM Transgenic Mouse Model for Alzheimer's Disease 2
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... 2014 Dr. Babatunde Osotimehin, Executive Director ... of a ceasefire agreement that is expected to lead ... who were kidnapped from the north-eastern Nigerian town of ... long enough, and it is high time they are ... Osotimehin. , "We owe it to these girls to ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides ... its latest designs of 2014 mother of the ... outfits are offered with big discounts, up to 70% ... 30 can enjoy this special offer. , Owing ... has become one of the leading brands in the ...
(Date:10/19/2014)... SUNDAY, Oct. 19, 2014 (HealthDay News) -- New stem ... eventually lead to new treatments, a new study suggests. ... functioning human intestinal tissue in a lab dish. They ... model for studying intestinal disorders, according to the researchers. ... many diseases and conditions that can cause intestinal failure, ...
(Date:10/19/2014)... Nearly 9,000 transvaginal mesh lawsuits ( ... Johnson’s Ethicon unit have now been centralized in New ... are continuing to move forward, Bernstein Liebhard LLP reports. ... over products part of Ethicon Inc.’s line of Gynecare ... 11th, 2014, which showed an additional 1,600 claims now ...
Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 4
... 16 (HealthDay News) -- Women with rheumatoid arthritis or ... hoped for, according to a new study. These ... cause fertility problems and miscarriage, researchers said. Lupus ... and organs. Rheumatoid arthritis leads to painful joint inflammation. ...
... HealthDay Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- ... of blood clots in people undergoing certain cancer treatments, ... treated with chemotherapy, they have an increased risk of ... dangerous, and have the potential to cause heart attacks ...
... Denise Mann HealthDay Reporter , WEDNESDAY, Feb. ... also help problem drinkers cut their alcohol consumption, a ... drug curbs drinking is not fully understood, but its ... of sadness and nausea, thereby blunting the pleasurable effects ...
... HealthDay Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- ... require driver,s education before getting a license, about one-third ... half fail to undergo any formal behind-the-wheel training. ... records were especially unlikely to have received driver,s ed ...
... 15, 2012 California reported the largest decline in drunk-driving ... to recent statistics, and a $232,000 grant from the California ... Safety Administration to UC Irvine,s Health Education Center is ... with the RADD College DUI Awareness Program, UCI has organized ...
... -- Takemi Tanaka, Ph.D., of Thomas Jefferson University,s School ... , received a $50,000 grant toward her breast cancer research, ... for Breast and Cervical Cancer Research" initiative. The ... who choose to contribute all or part of their state ...
Cached Medicine News:Health News:Lupus, Rheumatoid Arthritis Linked to Fertility Woes, Miscarriage 2Health News:New Blood Thinner May Prevent Blood Clots During Cancer Treatment 2Health News:New Blood Thinner May Prevent Blood Clots During Cancer Treatment 3Health News:Stop-Smoking Drug May Also Curb Problem Drinking 2Health News:Many U.S. Teens Hit the Road Without Driver's Ed: Survey 2Health News:Many U.S. Teens Hit the Road Without Driver's Ed: Survey 3Health News:UCI leads multicampus collaboration to reward use of designated drivers 2Health News:Taxpayers give back for cancer: Jefferson researcher awarded 'Refunds for Research' grant 2
... fixation. Completely resorbable, it presented surgeons with ... the most thoroughly proven product of its ... with system enhancements that make it even ... system means that application of this proven ...
... The intra-operative MR system ... intra-operative tool for radiologists ... goal of the system ... valuable adjunct to standard ...
... ultrasound A-scan Sonomed-315 is intended for visualization ... detection of midline shifts in the brain, ... and easy to use, the Sonomed-315 offers ... A-scanning mode allows to identify the anatomic ...
... With Plasmaseal's Proteus device the two steps ... is injected into Proteus' single use disposable ... base unit. The operator touches a button, ... is separated by centrifugation. Then the integral ...
Medicine Products: